c 171

STING-IN-3 (C-171) 是干扰素基因刺激物 (STING) 的抑制剂。 它与 STING 结合，抑制其棕榈酰化，并阻止 TBK1 的募集和磷酸化。

FX-171-C 作为一种非竞争性Deubiquitinase抑制剂，具有 1.4 µM 的IC50值。

EN4 (EN4 MYC inhibitor) 是一种靶向 M​​YC 的半胱氨酸 171 (C171) 的共价配体。它抑制 MYC 转录活性，下调 MYC 靶标，并具有抗肿瘤作用。它对 c-MYC 的选择性高于 N-MYC 和 L-MYC。

VPC171 是一种新型腺苷 A1 受体正变构调节剂 (PAM)。

ZINC17167211 is a selective peroxisome proliferator-activated receptors-α agonist.

JC-171 is a selective NLRP3 inflammasome inhibitor, with an IC50 of 8.45 μM for inhibiting LPS ATP-induced interleukin-1β (IL-1β) release from J774A.1 macrophages[1]. JC-171 (0-100 μM) blocks NLRP3 inflammasome activation and IL-1β production in primary macrophages dose dependently[1]. Cell Viability Assay[1] Cell Line: J774A.1 murine macrophage cells JC-171 treatment delays the progression and reduces the severity of experimental autoimmune encephalomyelitis (EAE) in mouse[1]. Animal Model: Mice immunized subcutaneously with 200 μg Myelin oligodendrocyte glycoprotein (MOG) 35-55 peptide emulsified in Complete Freund's Adjuvant (CFA) on day 0 followed by injection of 200 ng of pertussis toxin. [1]. Chunqing Guo, et al. Development and Characterization of a Hydroxyl-Sulfonamide Analogue, 5-Chloro-N-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a Novel NLRP3 Inflammasome Inhibitor for Potential Treatment of Multiple Sclerosis. ACS Chem Neurosci. 2017 Oct 18;8(10):2194-2201.

Ginkgolic acid C17:1 是分离自银杏叶中，通过诱导PTEN 和SHP-1酪氨酸磷酸酶抑制组成型和诱导型 STAT3 活化。它具有抗癌活性。

Ginkgolic Acids(C13:0,C15:1,C17:2,C15:0,C17:1) 是一种天然产物，可用作天然产物对照品，用于生命科学相关领域的研究，其产品编号为 TN8870。

SET-171 是一种 JNK (c-JunN-terminal kinase) 抑制剂，通过抑制肝脏丙酮酸激酶 (PKL) 的表达，展现出显著的抗癌特性和调节脂质代谢的潜力。在抗肿瘤研究中，SET-171 对人肝癌细胞系 HepG2 和 Huh7 的 IC50 值分别为 8.82 μM 和 2.97 μM，显示出较高的细胞毒性。此外，在非酒精性脂肪性肝病 (NAFLD) 的研究中，SET-171 显著降低三酰甘油 (TAG) 水平，并抑制与脂肪变性相关蛋白的表达。SET-171 有望用于肝细胞癌 (HCC) 和非酒精性脂肪性肝病的研究。

Purfalcamine is an orally active, selective Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) inhibitor with an IC50 of 17 nM and an EC50 of 230 nM. Purfalcamine has antimalarial activity and causes malaria parasites developmental arrest at the schizont stage[1][2]. Purfalcamine has low activity against Toxoplasma gondii calcium-dependent protein kinase 3 (TgCDPK3)[1]. Purfalcamine (225, 450 nM) has no effect on the parasitemia in the first 32 hours. After about 40 hours, parasite level remains stable and then begins dropping[1]. Purfalcamine inhibits proliferation with EC50s of 171-259 nM for P. falciparum strains (3D7, Dd2, FCB, HB3 and W2), which indicates effectiveness against drug-resistant parasites[1]. Given that the EC50 value for P. falciparum (3D7) is 230 nM, Purfalcamine shows a therapeutic window ranging from 23-fold to 36-fold (EC50s for CHO=12.33 μM, HEp2=7.235 μM, HeLa=7.029 μM and Huh7=5.476 μM)[1]. Purfalcamine (10 mg kg; oral gavage; BID; for 6 days) demonstrates a delay in the onset of parasitemia in treated mice[1]. Purfalcamine (20 mg kg; orally gavage) exhibits a Cmax of 2.6 μM with a half-life of 3.1 hours[1]. Animal Model: Male BALB c mice, 7 weeks of age with the malaria parasite[1] [1]. Nobutaka Kato, et al. Gene expression signatures and small-molecule compounds link a protein kinase to Plasmodium falciparum motility. Nat Chem Biol. 2008 Jun;4(6):347-56. [2]. Rajshekhar Y Gaji, et al. Expression of the essential Kinase PfCDPK1 from Plasmodium falciparum in Toxoplasma gondii facilitates the discovery of novel antimalarial drugs. Antimicrob Agents Chemother. 2014 May;58(5):2598-607.